Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 12/20 | 0.75 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.75 |
| ▸ | BUB1 | O43683 | 1/20 | 0.74 |
| ▸ | PRKACG | P22612 | 1/20 | 0.74 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.74 |
| ▸ | ACSL5 | Q9ULC5 | 1/20 | 0.74 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.74 |
| ▸ | HPGDS | O60760 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30335901 | 1.00 | MAPK14 (0.75) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3409256 | 0.93 | MAPK14 (0.75) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3411268 | 0.93 | MAPK14 (0.75) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3427765 | 0.92 | MAPK14 (0.71) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3412086 | 0.92 | MAPK14 (0.71) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3423690 | 0.92 | MAPK14 (0.74) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3409775 | 0.91 | MAPK14 (0.73) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL30335787 | 0.91 | MAPK14 (0.73) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3429381 | 0.91 | MAPK14 (0.75) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3531826 | 0.91 | MAPK14 (0.75) | MAPK14CYP2C9MAPK11BUB1PRKACG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258687-B1 | Nicotinamide derivates useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-12-26 | — | — | EP | claimed |
| EP-1474395-B1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-10-17 | — | — | EP | claimed |
| US-20220282254-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-09-08 | — | — | US | disclosed |
| CN-114748622-A | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | 弗尔康医疗公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-114732910-A | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-05-05 | — | — | US | disclosed |
| CN-111601593-B | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2022-04-15 | — | — | CN | disclosed |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20200383963-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. | 2020-12-10 | — | — | US | disclosed |
| CN-111601593-A | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2020-08-28 | — | — | CN | disclosed |
| EP-3691620-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| US-20100215652-A1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | ASTON NICOLA MARY | 2010-08-26 | — | — | US | disclosed |
| US-20100215661-A1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-08-26 | — | — | US | disclosed |
| US-7709506-B2 | Nicotinamide derivatives useful as p38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-05-04 | — | — | US | disclosed |
| EP-1864975-A2 | Novel compounds | SmithKline Beecham Corporation (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1474395-B1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-10-17 | — | — | EP | disclosed |
| US-7125898-B2 | Nicotinamide derivatives useful as p38 inhibitors. | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-24 | — | — | US | disclosed |
| US-20050176964-A1 | Nicotinamide derivatives useful as p38 inhibitors | GLAXOSMITHKLINE LLC | 2005-08-11 | — | — | US | disclosed |
| EP-1474395-A1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003068747-A1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885CYP2C9 4736/4885MAPK11 857/4885 |
| US-20200383963-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, RHOXF2 | MAPK14 193/4885CYP2C9 4718/4885MAPK11 726/4885 |
| US-20220282254-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885CYP2C9 4736/4885MAPK11 857/4885 |
| US-20100215661-A1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | MAPK1, MAPK7, MAPK4 | MAPK14 12/4885CYP2C9 2539/4885MAPK11 29/4885 |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885CYP2C9 4736/4885MAPK11 857/4885 |
| US-20100215652-A1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | MAPK1, MAPK7, MAPK4 | MAPK14 12/4885CYP2C9 2539/4885MAPK11 29/4885 |
| US-20050176964-A1 | Nicotinamide derivatives useful as p38 inhibitors | MAPK1, MAPK7, MAPK6 | MAPK14 10/4885CYP2C9 2948/4885MAPK11 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.